Literature DB >> 33486728

Mutant Mice and Animal Models of Airway Allergic Disease.

Julyanne Brassard1, David Marsolais1, Marie-Renee Blanchet2.   

Abstract

Eosinophilia is a hallmark of allergic airway inflammation, and eosinophils represent an integral effector leukocyte through their release of various granule-stored cytokines and proteins. Numerous mouse models have been developed to mimic clinical disease and they have been instrumental in furthering our understanding of the role of eosinophils in disease. Most of these models consist of intranasal (i.n.) administration of antigenic proteases including papain and house dust mite (HDM) or the neo-antigen ovalbumin, with a resulting Th2-biased immune response and airway eosinophilia. These models have been particularly informative when combined with the numerous transgenic mice available that modulate eosinophil frequency or the mechanisms involved in their migration. Here, we describe the current models of allergic airway inflammation and outline some of the transgenic mice available to study eosinophil disease.

Entities:  

Keywords:  Asthma; Eosinophil; Inflammation; Mouse

Year:  2021        PMID: 33486728     DOI: 10.1007/978-1-0716-1095-4_6

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  39 in total

1.  Occupational allergy to papain.

Authors:  M T Soto-Mera; M R López-Rico; J F Filgueira; E Villamil; R Cidrás
Journal:  Allergy       Date:  2000-10       Impact factor: 13.146

Review 2.  The expanding role(s) of eosinophils in health and disease.

Authors:  Elizabeth A Jacobsen; Richard A Helmers; James J Lee; Nancy A Lee
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

3.  CD34 is required for dendritic cell trafficking and pathology in murine hypersensitivity pneumonitis.

Authors:  Marie-Renée Blanchet; Jami L Bennett; Matthew J Gold; Elena Levantini; Daniel G Tenen; Melissa Girard; Yvon Cormier; Kelly M McNagny
Journal:  Am J Respir Crit Care Med       Date:  2011-06-03       Impact factor: 21.405

4.  CD34 is a specific marker of mature murine mast cells.

Authors:  Erin Drew; Helen Merkens; Shierley Chelliah; Regis Doyonnas; Kelly M McNagny
Journal:  Exp Hematol       Date:  2002-10       Impact factor: 3.084

5.  CD34 Differentially Regulates Contractile and Noncontractile Elements of Airway Reactivity.

Authors:  Katherine Lortie; Catherine Maheux; David Gendron; Anick Langlois; Marie-Josée Beaulieu; David Marsolais; Ynuk Bossé; Marie-Renée Blanchet
Journal:  Am J Respir Cell Mol Biol       Date:  2018-01       Impact factor: 6.914

Review 6.  Immunology of asthma and chronic obstructive pulmonary disease.

Authors:  Peter J Barnes
Journal:  Nat Rev Immunol       Date:  2008-02-15       Impact factor: 53.106

7.  CD34 facilitates the development of allergic asthma.

Authors:  Marie-Renée Blanchet; Steven Maltby; D James Haddon; Helen Merkens; Lori Zbytnuik; Kelly M McNagny
Journal:  Blood       Date:  2007-06-08       Impact factor: 22.113

8.  Homologous recombination into the eosinophil peroxidase locus generates a strain of mice expressing Cre recombinase exclusively in eosinophils.

Authors:  Alfred D Doyle; Elizabeth A Jacobsen; Sergei I Ochkur; Lian Willetts; Kelly Shim; Joseph Neely; Jake Kloeber; Will E Lesuer; Ralph S Pero; Paige Lacy; Redwan Moqbel; Nancy A Lee; James J Lee
Journal:  J Leukoc Biol       Date:  2013-04-29       Impact factor: 4.962

9.  Toll/IL-1 signaling is critical for house dust mite-specific helper T cell type 2 and type 17 [corrected] responses.

Authors:  Simon Phipps; Chuan En Lam; Gerard E Kaiko; Shen Yun Foo; Adam Collison; Joerg Mattes; Jessica Barry; Sophia Davidson; Kevin Oreo; Lauren Smith; Ashley Mansell; Klaus I Matthaei; Paul S Foster
Journal:  Am J Respir Crit Care Med       Date:  2009-02-26       Impact factor: 21.405

10.  Strain-specific requirement for eosinophils in the recruitment of T cells to the lung during the development of allergic asthma.

Authors:  Elizabeth Rose Walsh; Nisebita Sahu; Jennifer Kearley; Ebony Benjamin; Boo Hyon Kang; Alison Humbles; Avery August
Journal:  J Exp Med       Date:  2008-05-19       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.